Главная Назад


Авторизация
Идентификатор пользователя / читателя
Пароль (для удалённых пользователей)
 

Вид поиска

Область поиска
Найдено в других БД
Формат представления найденных документов:
библиографическое описаниекраткийполный
Отсортировать найденные документы по:
авторузаглавиюгоду изданиятипу документа
Поисковый запрос: (<.>S=СОВМЕСТНОЕ МЕСТНОЕ ПРИМЕНЕНИЕ<.>)
Общее количество найденных документов : 2
Показаны документы с 1 по 2
1.
РЖ ВИНИТИ 76 (BI31) 96.08-04Т3.422

   

    Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate [Text] / J. Soto [et al.] // Clin. Infec. Diseases. - 1995. - Vol. 20, N 1. - P47-51 . - ISSN 1058-4838
Перевод заглавия: Успешное лечение кожного лейшманиоза Нового Света при объединении местной терапии паромомицином/метилбензетония хлоридом и парентерального введения меглумина антимоната
Аннотация: Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg*d]). Cohort 1 received topical therapy for 10 days and Sb for 7 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 7-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis
ГРНТИ  
ВИНИТИ 761.31.29.35.21.15
Рубрики: ЛЕЙШМАНИОЗ
КОЖНЫЙ

ПАРОМОМИЦИН

МЕТИЛБЕНЗЕТОНИЯ ХЛОРИД

СОВМЕСТНОЕ МЕСТНОЕ ПРИМЕНЕНИЕ

МЕГЛУМИНА АНТИМОНАТ

ПАРЕНТЕРАЛЬНОЕ ВВЕДЕНИЕ

БОЛЬНЫЕ


Доп.точки доступа:
Soto, J.; Hernandez, N.; Mejia, H.; Grogl, M.; Berman, J.


2.
РЖ ВИНИТИ 34 (BI50) 96.11-04И2.60

   

    Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate [Text] / J. Soto [et al.] // Clin. Infec. Diseases. - 1995. - Vol. 20, N 1. - P47-51 . - ISSN 1058-4838
Перевод заглавия: Успешное лечение кожного лейшманиоза Нового Света при объединении местной терапии паромомицином/метилбензетония хлоридом и парентерального введения меглумина антимоната
Аннотация: Colombian patients with New World cutaneous leishmaniasis were treated with a combination of a topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and parenteral meglumine antimonate (20 mg of antimony [Sb]/[kg*d]). Cohort 1 received topical therapy for 10 days and Sb for 7 days; 18 (90%) of the 20 patients were cured (follow-up, 12 months). Other clinical data suggested that neither the topical formulation alone nor the 7-day regimen of Sb alone would have cured many patients. In a subsequent cohort, which received topical therapy for 10 days and Sb for 3 days, the cure rate was 42% (eight of 19 patients). In Colombian cohorts (historical controls) treated with Sb alone for 10-15 days, the cure rate was 31%-36%. Side effects in cohort 1 patients consisted of local reactions to the topical formulation: burning and pruritis in 25% of patients and vesicle formation in 15% of patients. This is the first report that a regimen partially composed of topical antimicrobial agents can be highly effective for treatment of New World cutaneous leishmaniasis
ГРНТИ  
ВИНИТИ 341.33.23.15.13.07.11.21
Рубрики: ЛЕЙШМАНИОЗ
КОЖНЫЙ

ПАРОМОМИЦИН

МЕТИЛБЕНЗЕТОНИЯ ХЛОРИД

СОВМЕСТНОЕ МЕСТНОЕ ПРИМЕНЕНИЕ

МЕГЛУМИНА АНТИМОНАТ

ПАРЕНТЕРАЛЬНОЕ ВВЕДЕНИЕ

БОЛЬНЫЕ


Доп.точки доступа:
Soto, J.; Hernandez, N.; Mejia, H.; Grogl, M.; Berman, J.


 




© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)